Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.

Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.

Abstract: A method of manufacturing an electrical device, comprising: forming a patterned inorganic liftoff layer to expose a target electrode site on a softening polymer layer, depositing an electrode layer on the inorganic liftoff layer and on the exposed target electrode site, and removing the inorganic liftoff layer by a horizontal liftoff etch to leave the electrode layer on the exposed target electrode site.

Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.

Abstract: The present techniques may provide improved processing and functionality of performance of the 128-bit AES Algorithm, which may provide improved power consumption. For example, in an embodiment, an encryption and decryption apparatus may comprise memory storing a current state matrix of an encryption or decryption process and a plurality of multiplexers configured to receive from the memory current elements of the state matrix stored in the memory, perform a cyclic shift on the received elements of the state matrix, and transmit the shifted elements to the memory for storage as a new state matrix.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

Abstract: Systems, methods, and techniques are described herein for characterizing well treatment fluids and well treatment fluid performance. For example, well treatment fluids can be characterized using microfluidic chips to determine fluid properties, with very small amounts of fluid used for the characterization process. Optical analysis and electrical conductivity analysis of well treatment fluids as they pass through different microfluidic pathways with different cross-sectional dimensions can be used to gain information about the well treatment fluid's composition, structure, and performance. In some cases, microfluidic pathways can be functionalized as a model for a wellbore and a reservoir (e.g., rock in the reservoir) to evaluate the performance of well treatment fluids by imaging the well treatment fluid as it flows into or through the functionalized model. These systems, methods, and techniques can allow for optimization of well treatment fluids prior to or during drilling or completion operations.

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.

Abstract: Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R). The CAR targeted to BAFF-R (BAFF-R CAR) described herein includes a domain that binds BAFF-R. Methods of making and using the BAFF-R CAR are also provided.

Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: Mid-IR light emitting diodes (LEDs) based on type-II quantum dot (QD) active regions grown with monolithically integrated semiconductor metal layers are provided. These LEDs comprise layers of type-II semiconductor (e.g., InGaSb) quantum dots integrated into a pn junction diode (e.g., InAs) grown above a highly doped backplane, such as an n++ InAs backplane, all in the same epitaxial growth. Aspects described herein minimize non-radiate recombination times and significantly increase radiative recombination rates by controlling the emission of the emitting QDs in the near field of an optical metal.

Abstract: A method of measuring fluid flow rate is provided. The method comprises positioning a piezoelectric sensor in a fluid flow stream and measuring a voltage output from the piezoelectric sensor caused by mechanical stress from the fluid flow stream. A fluid flow rate is calculated based on the measured voltage output according to predefined relationships between the voltage output and a number physical parameters.

Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).

Abstract: This technology relates to polynucleotides comprising optimized FMR1 open reading frame (ORF) sequences, viral vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of FMR1, such as Fragile X syndrome (“FXS”).

Abstract: The present invention relates generally to the fields of medicine, immunology, and cancer biology. More particularly, it concerns antibodies that target HSP70 and methods of their use. Provided herein are agents such as antibodies that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent such as an HSP70-specific antibody. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.

Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).

Abstract: The present invention relates to compositions comprising transmembrane stem cell factor (tmSCF) polypeptide embedded in a lipid vesicle and methods of use thereof. In some embodiments, the lipid vesicle is a nanocarrier. Disclosed herein is a method for promoting angiogenesis in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a tmSCF polypeptide embedded in a lipid vesicle. Disclosed herein is a method for treating a subject with peripheral vascular disease (PVD), comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a tmSCF polypeptide.

Abstract: Methods and systems for assisting tonally-challenged singers. A microphone can be integrated with a sound reinforcement system used in a live performance. The microphone, which can transduce the performer's voice, can serve multiple purposes such as, for example, to feed input to the natural ear and to the sound reinforcement system. The processed sound of the performer's voice (with fundamental frequency emphasized) can be mixed into the signal fed to a stage “monitor” speaker facing the performer or a headset worn by the performer.